A5023200887- BRCA gene mutations in cancer
- Advanced Breast Cancer Therapies
- Cancer Genomics and Diagnostics
- PARP inhibition in cancer therapy
- HER2/EGFR in Cancer Research
- Breast Cancer Treatment Studies
- Fibroblast Growth Factor Research
- Cancer Cells and Metastasis
- RNA modifications and cancer
- Male Breast Health Studies
- Lung Cancer Treatments and Mutations
- Cancer Treatment and Pharmacology
- Estrogen and related hormone effects
- Cancer Immunotherapy and Biomarkers
- DNA Repair Mechanisms
- Neuroendocrine Tumor Research Advances
- Health Systems, Economic Evaluations, Quality of Life
- Cancer Diagnosis and Treatment
- Eosinophilic Disorders and Syndromes
- Genetics, Bioinformatics, and Biomedical Research
- Breast Lesions and Carcinomas
- Global Healthcare and Medical Tourism
- Cancer and Skin Lesions
- Radiopharmaceutical Chemistry and Applications
- Multiple and Secondary Primary Cancers
Breast International Group
2015-2025
Association des Operateurs Postaux Publics Europeens
2022-2024
Roche (Switzerland)
2019
European Institute of Oncology
2019
Institut Jules Bordet
2017-2019
Dana-Farber Cancer Institute
2016-2019
Alliance Foundation Trials
2019
Cedars-Sinai Medical Center
2016-2019
Indiana University – Purdue University Indianapolis
2016-2018
The Netherlands Cancer Institute
2018
The 70-gene signature test (MammaPrint) has been shown to improve prediction of clinical outcome in women with early-stage breast cancer. We sought provide prospective evidence the utility addition standard clinical–pathological criteria selecting patients for adjuvant chemotherapy.
The FGFR1 gene is amplified in 14% of patients with HR + /HER2 - breast cancer. Efficacy and safety lucitanib, an inhibitor VEGFR1-3, FGFR1-3, PDGFRα/β, were assessed.Patients metastatic cancer (MBC) received oral lucitanib three centrally confirmed cohorts: (i) amplified, (ii) nonamplified, 11q13 (iii) nonamplified. Key inclusion criteria included Eastern Cooperative Oncology Group Performance Status ≤2, ≥1 line anticancer therapy, but ≤2 lines chemotherapy. Primary endpoint was overall...
Abstract Intro: Male BC is a rare disease (<1% male tumors); knowledge limited and management extrapolated from female BC. An international consortium, coordinated by EORTC TBCRC, was created to better characterize manage this disease, with 3 parts: 1) retrospective joint analysis 2) prospective registry 3) clinical trial(s). We report 1st results of part 1. Methods: Joint pts available FU & FFPE samples, treated in 1990-2010, 23 centers 9 countries. Clinical data, long term...
Abstract Background: The MINDACT TRIAL investigated the clinical utility of 70-gene profile (MammaPrint®), when confronted to standard pathological (CP) criteria, for selection patients unlikely benefit from adjuvant chemotherapy (CT).Methods: From 2007 2011, 11288 were screened in 112 centers 9 countries, whom 6693 enrolled. Enrolled had undergone successful determination their genomic risk G (with MammaPrint®) and C (modified version Adjuvant! Online). Patients evaluated as “low risk”, if...
Abstract Background: About 30% of patients (pts) with hormone receptor (HR)-positive early breast cancer (EBC) on adjuvant aromatase inhibitor (AI) therapy discontinue due to toxicity 22% pts discontinuing during the first year (Henry et al. JCO 2012). For these who struggle AIs, there are limited alternatives including switch a different AI which may have similar side effects, tamoxifen, or observation. This paucity effective and tolerable options contribute poor adherence and/or...
Despite recent advances in breast cancer research, we still know little about the mechanisms that lead to metastatic (MBC). However, treatment options for patients have increased based on results of randomized clinical trials this setting. Today much hope, yet many questions remain unanswered. Conducting a fully academic and international study such as AURORA is very challenging, ever more crucial advancing knowledge MBC.
TPS659 Background: Germline mutations of BRCA1/BRCA2 genes are a cause hereditary breast or ovarian cancer. Cancers arising in women with germline defective DNA repair, and BRCA deficient cancer cells hypersensitive to PARP inhibitors (Bryant et al., 2005;Farmer 2005). Niraparib is potent,selective inhibitor PARP-1 PARP-2 that demonstrated activity BRCA1 BRCA2 mutated cell lines. Responses have been reported BRCA1.2 related (Michie al, 2013). Methods: Patients HER2 negative metastatic (306),...
TPS607 Background: There are currently limited treatment options for patients with HR+ EBC who have discontinued adjuvant aromatase inhibitors (AIs) due to treatment-related toxicity. Amcenestrant is an optimized oral selective estrogen receptor degrader (SERD) potent dual activity which antagonizes and degrades the ER resulting in inhibition of signalling pathway. Preliminary clinical evidence from phase 1/2 AMEERA-1 trial has demonstrated meaningful antitumour a favourable safety profile...
Abstract Background Germline BRCA mutations (gBRCAmut) amongst breast cancer (BC) patients ranges between 5% - 25% depending on family history of BC or ovarian (OC). Cells treated with PARP inhibitors (PARPi) accumulate defects that lead to their death in the absence homologous recombination (HR) repair (e.g. gBRCAmut). Niraparib is a PARPi development. As TNT study showed better results 1st line carboplatin vs docetaxel gBRCAmut patients, rise platinum-exposed population expected. Due prior...
Clinical trials cooperation is not a luxury; it necessity, now more than ever, first in light of the segmentation tumors according to their molecular targets—which are being matched an increasing number competitive drugs—and second because only chance maintain academic research centered on addressing patients’ needs. In its 21 years existence, Breast International Group, umbrella organization supporting activities 54 member groups across six continents, has been confronted with challenges...
TPS1134 Background: FGF aberrancy is observed in approximately 25% of breast cancer (BC) patients. Preclinical studies demonstrated that targeting FGFR could lead to antitumor effects. Lucitanib a multikinase inhibitor FGFR1-2, VEGFR1-3 and PDGFRA/B. In the phase I trial testing lucitanib continuous dosing, 6 objective responses were 12 evaluable patients presenting with FGFR1 and/or FGF3-4-19 (11q) amplification. Based on this, II has been initiated. Methods: This efficacy 15 mg daily...
Abstract Background: Cell cycle inhibition is a target of interest for novel cancer therapeutics. Palbociclib (P) an orally active inhibitor CDK4/6 which arrests the cell at G1-S transition. P has demonstrated efficacy in phase II and III randomized trials first-line pre-treated hormone receptor positive/HER2 negative (HR+/HER2-) metastatic breast (MBC), with hazard ratios 0.42-0.49 (Finn et al, Lancet Oncol 2015, Turner NEJM 2015), approved combination letrozole as therapy HR+/HER2- MBC....
516 Background: The MINDACT trial demonstrated that 46% of breast cancer patients (pts) at high clinical (C) but low genomic (G) risk based on MammaPrint (70-gene signature), might safely forego adjuvant CT (Cardoso NEJM 2016). A second 1:1 randomization (R-C) was optional in all pts for whom decided, between standard anthracycline-based regimens (AT) and experimental docetaxel 75 mg/m² IV + oral capecitabine 825 bid x 14 days (DC), q3wks 6 cycles after surgery. Methods: included 6693 pts,...